Pipeline
R&D GMP
Scale-Up Clinical
Trials Registration
Filing
Current Stage: GMP Scale-Up
Optimizing manufacturing processes for clinical-grade production.
Current Stage: Exploratory R&D
Conducting early-stage feasibility and efficacy studies.
Current Stage: Exploratory R&D
Investigating potential for fertility restoration applications.
Current Stage: GMP Scale-Up
Scaling up exosome isolation and purification protocols.
Current Stage: Exploratory R&D
Targeting orphan disease designation for HIE treatment.
Current Stage: Exploratory R&D
Researching mitochondrial transfer mechanisms for therapy.
Applications of Our Expertise
Our collaborative pipeline focuses on pioneering drug, vaccine, and cellular therapies to address unmet medical needs and improve patient outcomes worldwide.
Introduction to Collaboration
The partnership between theInternational French Malaysian Natural Products Laboratory (IFM NATPROLAB), University of Malaya, and Inno Therapeutics aims to establish a synergistic collaboration in advancing the frontiers of drug discovery.
This collaboration leverages IFM NATPROLAB’s expertise in natural products research with Inno Therapeutics’ vision of pioneering innovative therapeutics, particularly in the domains of drug, vaccine, and cellular therapeutics.
Shared Vision
The collaboration is dedicated to accelerating the development of novel drugs, improving therapeutic outcomes, and fostering translational research that bridges the gap between laboratory innovation and clinical applications.
Key Areas of Collaboration
- Natural Product-Based Drug Discovery
- Screening and identification of bioactive compounds from Malaysia’s rich biodiversity.
- Optimization of lead compounds for therapeutic use in oncology, infectious diseases, and chronic conditions.
- Advanced Drug Development
- Integration of computational modeling and bioinformatics in lead compound identification.
- Preclinical development, including pharmacokinetics, toxicity studies, and formulation optimization.
- Cellular Therapeutics and Biologics
- Joint research on integrating natural products with cellular therapy innovations, including cellular platforms.
- Investigating synergistic effects of natural products in enhancing the efficacy of cellular therapies.
- Training and Capacity Building
- Training early-career researchers in drug discovery methodologies, natural product analytics, and therapeutic development.
- Knowledge exchange through workshops, seminars, and shared laboratory resources.
- Intellectual Property (IP) Development and Commercialization
- Joint efforts in securing IP rights for novel compounds and technologies.
- Development of strategic pathways for commercialization and industry partnerships.
Strengths of IFM NATPROLAB
- Established expertise in exploring natural products as potential therapeutic agents.
- State-of-the-art facilities for compound isolation, chemical synthesis, and bioactivity screening.
- Strong track record in publishing high-impact research and engaging in international collaborations.
Strengths of Inno Therapeutics
- Strong focus on drug discovery and cellular therapeutic research and development.
- Industry-oriented expertise in transforming laboratory discoveries into market-ready products.
- Commitment to enhancing Malaysia’s role in the global biotechnology and pharmaceutical landscape.
Outcomes and Impact
This collaboration is expected to yield:
- Novel therapeutic candidates addressing unmet medical needs.
- Strengthened research capacity in Malaysia through collaborative efforts.
- Enhanced contributions to the global drug discovery and development pipeline.
Introduction to Collaboration
The partnership between the Centre for Natural Products Research and Drug Discovery (CENAR), University of Malaya, and Inno Therapeutics aims to establish a synergistic collaboration in advancing the frontiers of drug discovery.
This collaboration leverages CENAR’s expertise in natural products research with Inno Therapeutics’ vision of pioneering innovative therapeutics, particularly in the domains of drug, vaccine, and cellular therapeutics.
Shared Vision
The collaboration is dedicated to accelerating the development of novel drugs, improving therapeutic outcomes, and fostering translational research that bridges the gap between laboratory innovation and clinical applications.
Key Areas of Collaboration
- Natural Product-Based Drug Discovery
- Screening and identification of bioactive compounds from Malaysia’s rich biodiversity.
- Optimization of lead compounds for therapeutic use in oncology, infectious diseases, and chronic conditions.
- Advanced Drug Development
- Integration of computational modeling and bioinformatics in lead compound identification.
- Preclinical development, including pharmacokinetics, toxicity studies, and formulation optimization.
- Cellular Therapeutics and Biologics
- Joint research on integrating natural products with cellular therapy innovations, including cellular platforms.
- Investigating synergistic effects of natural products in enhancing the efficacy of cellular therapies.
- Training and Capacity Building
- Training early-career researchers in drug discovery methodologies, natural product analytics, and therapeutic development.
- Knowledge exchange through workshops, seminars, and shared laboratory resources.
- Intellectual Property (IP) Development and Commercialization
- Joint efforts in securing IP rights for novel compounds and technologies.
- Development of strategic pathways for commercialization and industry partnerships.
Strengths of CENAR
- Established expertise in exploring natural products as potential therapeutic agents.
- State-of-the-art facilities for compound isolation, chemical synthesis, and bioactivity screening.
- Strong track record in publishing high-impact research and engaging in international collaborations.
Strengths of Inno Therapeutics
- Strong focus on drug discovery and cellular therapeutic research and development.
- Industry-oriented expertise in transforming laboratory discoveries into market-ready products.
- Commitment to enhancing Malaysia’s role in the global biotechnology and pharmaceutical landscape.
Outcomes and Impact
This collaboration is expected to yield:
- Novel therapeutic candidates addressing unmet medical needs.
- Strengthened research capacity in Malaysia through collaborative efforts.
- Enhanced contributions to the global drug discovery and development pipeline.
Introduction to Collaboration
The Biotechnology Research Institute (BRI), Faculty of Science and Natural Resources, University Malaysia Sabah (UMS), and Inno Therapeutics are establishing a strategic partnership aimed at advancing cellular therapy and vaccine discovery research. This collaboration combines BRI’s cutting-edge expertise in biotechnology and molecular biology with Inno Therapeutics’ industry-driven focus on innovative therapeutics, particularly in cellular therapy and vaccines.
Shared Vision
The collaboration is committed to strengthening Malaysia’s position as a global leader in cellular therapy and vaccine discovery. Through innovative research and development, the partnership aims to address pressing medical challenges, enhance healthcare outcomes, and foster scientific excellence.
Key Areas of Collaboration
- Cellular Therapy Research
- Joint research on mesenchymal stem cells and menstrual stem cells for regenerative therapy.
- Developing isolation protocol for autologous cellular therapy clinical applications.
- Vaccine Discovery and Development
- Research into novel vaccine candidates for emerging infectious diseases, including zoonotic pathogens endemic to Sabah and the region.
- Development of mRNA, DNA, and recombinant protein-based vaccine platforms.
- Collaborative preclinical testing of vaccine candidates for safety and efficacy.
- Training and Human Capital Development
- Joint training programs for postgraduate students and researchers in vaccine development and cellular therapy.
- Organization of workshops, symposiums, and exchange programs to share technical expertise.
- Intellectual Property (IP) Development and Commercialization
- Protection and management of IP arising from the collaboration.
- Establishing commercialization pipelines for vaccine and cellular therapy products.
Strengths of BRI, UMS
- Renowned for research in tropical biodiversity, molecular biology, and biotechnology.
- Strong focus on microbiome research and high-throughput sequencing technologies.
- Expertise in bioprospecting and utilizing Sabah’s rich natural resources for scientific innovation.
Strengths of Inno Therapeutics
- A mission-driven focus on developing advanced therapeutics in cellular therapy and vaccines.
- Strong industry knowledge and a translational approach to R&D.
- Commitment to addressing healthcare challenges through cutting-edge innovations.
Anticipated Outcomes
This collaboration is expected to deliver:
- Novel cellular therapy products and vaccine candidates for clinical development.
- Strengthened R&D capacity in Malaysia with a focus on regional healthcare priorities.
- Accelerated translation of research findings into impactful healthcare solutions.
Introduction to Collaboration
The Faculty of Science, National University of Malaysia (UKM), and Inno Therapeutics have established a strategic partnership to enhance talent development in the fields of biotechnology, cellular therapy, and pharmaceutical sciences. This collaboration aims to bridge the gap between academic excellence and industry needs by equipping students and researchers with the necessary skills and experience to contribute to Malaysia’s growing biopharmaceutical sector.
Shared Vision
This collaboration is dedicated to fostering a pipeline of highly skilled professionals in biomedical research, drug discovery, and advanced therapeutics. By combining UKM’s academic expertise with Inno Therapeutics’ industry-driven focus, the partnership aims to cultivate a new generation of scientists and innovators who will drive Malaysia’s position as a leader in regenerative medicine, cellular therapy, and drug development.
Key Areas of Collaboration
1. Internship and Industrial Training Programs
- Structured internships for UKM undergraduate and postgraduate students at Inno Therapeutics’ research and manufacturing facilities.
- Hands-on experience in cellular therapy, vaccine development, and biopharmaceutical production.
- Exposure to Good Manufacturing Practice (GMP) and Good Laboratory Practice (GLP) environments.
2. Joint Research & Innovation Projects
- Collaborative R&D projects focused on drug discovery, regenerative medicine, and immunotherapy.
- Opportunities for students to participate in real-world scientific research with industry applications.
- Co-development of innovative solutions addressing healthcare challenges in Malaysia.
3. Postgraduate Supervision & Scholarships
- Co-supervision of MSc and PhD students working on projects aligned with Inno Therapeutics’ research priorities.
- Research funding and scholarships for outstanding postgraduate students.
- Access to Inno Therapeutics’ state-of-the-art laboratories and mentorship from industry experts.
4. Training Workshops & Skill Development
- Specialized training programs in cell culture, stem cell therapy, bioprocessing, and molecular biology techniques.
- Workshops on regulatory compliance, clinical translation, and commercialization of biopharmaceutical products.
- Development of leadership and entrepreneurial skills for students interested in biotech startups.
5. Knowledge Exchange & Public Engagement
- Joint organization of conferences, symposiums, and knowledge-sharing sessions on advanced biotechnologies.
- Public awareness initiatives on the role of regenerative medicine and cellular therapy in healthcare.
- Collaborative publications and white papers highlighting advancements in biomedical research.
Strengths of the Faculty of Science, UKM
- A strong academic foundation in biosciences, biotechnology, and pharmaceutical sciences.
- Advanced research facilities and laboratories dedicated to biological and medical sciences.
- A track record of producing highly skilled graduates in biomedical fields.
Strengths of Inno Therapeutics
- Industry expertise in drug discovery, cellular therapy, and vaccine development.
- Strong translational research approach bridging laboratory discoveries to clinical applications.
- Commitment to workforce development and capacity building in Malaysia’s biotechnology sector.
Anticipated Outcomes
- A well-trained talent pool equipped with industry-relevant skills in biomedical and pharmaceutical sciences.
- Strengthened collaboration between academia and industry to drive innovation and research commercialization.
- Enhanced career prospects for UKM graduates in the biotechnology and pharmaceutical industries.
Introduction to Collaboration
The Neural Stem Cells Research Group (NSCSRG), School of Health Sciences, University of Science Malaysia (USM), and Inno Therapeutics have joined forces to advance research on dental pulp stem cells (DPSCs) for neuroregeneration and neuroprotection therapy. This collaboration integrates NSCSRG’s cutting-edge expertise in neural stem cell biology with Inno Therapeutics’ focus on cellular therapy innovation to address neurodegenerative diseases and neural injury.
Shared Vision
This partnership is committed to pioneering new frontiers in regenerative neuroscience by leveraging the therapeutic potential of dental pulp stem cells. The collaboration aims to develop groundbreaking therapies that restore neural function, protect against neurodegeneration, and improve quality of life for patients with neurological disorders.
Key Areas of Collaboration
- Dental Pulp Stem Cell (DPSC) Research
- Isolation, characterization, and expansion of DPSCs for therapeutic applications.
- Investigating the neuroregenerative potential of DPSCs in repairing damaged neural tissues.
- Optimization of DPSC differentiation into neurons and glial cells for targeted therapies.
- Neuroprotection Therapy Development
- Exploring DPSCs’ role in reducing oxidative stress, inflammation, and apoptosis in neurodegenerative conditions.
- Developing DPSC-based therapies for diseases such as Alzheimer’s, Parkinson’s, and spinal cord injuries.
- Studying paracrine signaling mechanisms and exosome-mediated effects of DPSCs on neural tissues.
- Preclinical Research and Validation
- Animal model studies to evaluate the efficacy of DPSC-based neuroregenerative and neuroprotective therapies.
- Assessment of safety profiles, biodistribution, and long-term outcomes in preclinical settings.
- Developing translational pathways for advancing promising candidates to clinical trials.
- Training and Knowledge Sharing
- Joint programs for training researchers and clinicians in DPSC isolation, culture, and therapeutic applications.
- Collaborative workshops, seminars, and conferences to disseminate research findings.
- Development of educational materials on the potential of DPSCs in regenerative neuroscience.
- Intellectual Property (IP) and Commercialization
- Co-development and protection of IP for novel therapies using DPSCs for neuroregeneration.
- Strategic commercialization of products and establishment of industry partnerships.
- Collaborative efforts to secure funding for translational research initiatives.
Strengths of NSCSRG, USM
- Renowned expertise in neural stem cell research and regenerative medicine.
- State-of-the-art facilities for cell culture, molecular biology, and preclinical studies.
- Strong focus on addressing neurodegenerative diseases and neural repair.
Strengths of Inno Therapeutics
- Expertise in cellular therapy research and development, with a focus on innovative therapeutic solutions.
- Industry knowledge in advancing therapies from research to clinical application.
- Commitment to fostering innovation in Malaysia’s biomedical landscape.
Anticipated Outcomes
- Development of advanced DPSC-based therapies for neuroregeneration and neuroprotection.
- Strengthened research capabilities in Malaysia in the field of regenerative neuroscience.
- Significant contributions to addressing global healthcare challenges in neurodegenerative diseases.
Introduction to Collaboration
The partnership between Taiwan Bio Therapeutics and Inno Therapeutics focuses on the development of innovative cellular therapies leveraging Mesenchymal Stem Cell (MSC)-derived exosomes, engineered MSCs, and T regulatory cells (Tregs). By combining Taiwan Bio Therapeutics’ advanced expertise in stem cell engineering and exosome technology with Inno Therapeutics’ strategic focus on translational therapeutics, this collaboration aims to revolutionize regenerative medicine and immune modulation therapies.
Shared Vision
This partnership envisions accelerating the development of next-generation cellular therapies to address critical unmet medical needs in immunological disorders, inflammatory diseases, and tissue repair. Through collaborative innovation, the partnership aims to deliver transformative therapies that improve patient outcomes globally.
Key Areas of Collaboration
- MSC-Derived Exosomes
- Isolation and characterization of exosomes from MSCs for therapeutic applications.
- Investigating the immunomodulatory, anti-inflammatory, and regenerative properties of exosomes.
- Development of scalable GMP-compliant processes for exosome production and clinical-grade formulation.
- Engineered Mesenchymal Stem Cells (MSCs)
- Development of genetically modified MSCs to enhance therapeutic efficacy and targeting specificity.
- Preclinical studies to evaluate engineered MSCs for tissue regeneration and immune modulation.
- Exploring applications in oncology, fibrosis, and chronic inflammatory conditions.
- T Regulatory Cells (Tregs)
- Research on ex vivo expansion and engineering of Tregs for immune tolerance therapies.
- Development of Treg therapies for autoimmune diseases, graft-versus-host disease (GvHD), and transplant rejection.
- Investigating combinatory approaches using Tregs and MSC-derived exosomes for enhanced immunomodulation.
- Preclinical and Clinical Translation
- Joint preclinical studies to validate safety, efficacy, and mechanism of action.
- Development of clinical protocols for phase I and II trials targeting priority indications.
- Establishing regulatory pathways and compliance for advanced therapeutic products.
- Knowledge Exchange and Workforce Development
- Joint training programs and exchange of expertise in stem cell engineering and exosome biology.
- Organization of workshops, conferences, and publications to disseminate research outcomes.
- Development of a talent pipeline for advancing regenerative medicine expertise in the region.
- Intellectual Property (IP) and Commercialization
- Co-development and protection of IP for MSC-based and Treg-based therapies.
- Strategic pathways for product commercialization and global market entry.
- Collaborative efforts to attract funding and strategic partnerships.
Strengths of Taiwan Bio Therapeutics
- Industry-leading expertise in MSC-derived exosomes and stem cell engineering technologies.
- Proven track record in developing advanced cellular therapy platforms.
- Cutting-edge facilities and a robust focus on translational research.
Strengths of Inno Therapeutics
- Commitment to advancing innovative cellular and immune-based therapies.
- Strong focus on translational research, bridging laboratory discoveries to clinical application.
- Strategic vision for enhancing Malaysia’s contribution to the global biotherapeutics landscape.
Anticipated Outcomes
- Development of novel therapeutic candidates using MSC-derived exosomes, engineered MSCs, and Tregs.
- Acceleration of clinical translation for high-impact therapeutic solutions.
- Significant contributions to the global field of regenerative medicine and immune therapy.
Introduction to Collaboration
The partnership between Gwo Xi Stem Cell Applied Technology Co., Ltd, a leader in stem cell technology, and Inno Therapeutics, a pioneer in advanced therapeutics in Malaysia, is dedicated to advancing the development and application of adipose-derived stem cells (ADSCs) for diabetes treatment. This collaboration aims to provide innovative and effective therapies addressing one of Malaysia’s most pressing healthcare challenges—diabetes mellitus and its complications.
Shared Vision
The collaboration seeks to establish Malaysia as a regional hub for regenerative medicine by leveraging Gwo Xi Stem Cell Applied Technology Co., Ltd’s expertise in ADSC technology and Inno Therapeutics’ focus on translational medicine. Together, the partnership will accelerate the discovery, development, and delivery of ADSC-based therapies to improve the lives of diabetic patients.
Key Areas of Collaboration
- Adipose-Derived Stem Cell Research
- Investigating the potential of ADSCs in promoting beta-cell regeneration, reducing insulin resistance, and modulating inflammatory pathways.
- Development of advanced protocols for harvesting and optimizing ADSCs for diabetes treatment.
- Preclinical and Clinical Applications
- Conducting preclinical studies to evaluate the safety, efficacy, and mechanisms of ADSCs in diabetes management.
- Designing and implementing clinical trials in Malaysia, focusing on diabetes and associated complications such as neuropathy, nephropathy, and wound healing.
- Collaborating with healthcare institutions to ensure seamless clinical translation of ADSC-based therapies.
- Therapeutic Product Development
- Developing scalable Good Manufacturing Practice (GMP)-compliant methods for ADSC production.
- Exploring delivery methods, including intravenous infusion and localized administration, for targeted treatment.
- Ensuring product stability and regulatory compliance for ADSC-based treatments.
- Training and Knowledge Sharing
- Joint training programs for Malaysian researchers and clinicians in ADSC isolation, expansion, and therapeutic applications.
- Workshops and seminars to raise awareness about regenerative medicine solutions for diabetes.
- Development of academic and industry networks to promote collaborative research.
- Regulatory and Commercialization Strategies
- Co-developing pathways to secure regulatory approval for ADSC-based therapies in Malaysia and the region.
- Exploring commercialization strategies to make ADSC therapies accessible to Malaysian patients.
- Building partnerships with local healthcare providers and stakeholders to integrate ADSC treatments into clinical practice.
Strengths of Gwo Xi Stem Cell Applied Technology Co., Ltd
- Pioneering expertise in stem cell isolation, expansion, and clinical application, with a focus on ADSCs.
- State-of-the-art facilities and a proven track record of developing stem cell-based therapeutics.
- Strong presence in the global regenerative medicine market.
Strengths of Inno Therapeutics
- Strategic focus on developing innovative cellular therapies tailored to Malaysia’s healthcare needs.
- Expertise in translational research and a strong network within the local healthcare ecosystem.
- Commitment to advancing Malaysia’s position in the global biotherapeutics industry.
Anticipated Outcomes
- Development of safe and effective ADSC-based therapies for diabetes management and its complications.
- Improved healthcare outcomes for Malaysian patients through cutting-edge regenerative medicine solutions.
- Enhanced research and development capacity in Malaysia, fostering innovation in the field of stem cell therapy.
Introduction to Collaboration
BioMab Inc., a global leader in the development of advanced culture media and biomedical tools, and Inno Therapeutics, a Malaysia-based pioneer in cellular therapeutics and biopharmaceuticals, have joined forces to support the development of high-quality culture media and isolation kits tailored for diverse biomedical applications. This partnership aims to facilitate cutting-edge research and accelerate the production of therapeutic solutions, contributing to advancements in the fields of regenerative medicine, cell therapy, and vaccine development.
Shared Vision
The collaboration seeks to enable researchers and clinicians with state-of-the-art tools and resources for cellular and molecular biology. By leveraging BioMab’s expertise in media and isolation technologies and Inno Therapeutics’ focus on translational medicine, the partnership aims to establish Malaysia as a hub for biomedical innovation.
Key Areas of Collaboration
- Culture Media Development
- Co-development of customized culture media for stem cells, immune cells (e.g., NK cells, MSCs), and other cell types critical for therapeutic applications.
- Optimization of media formulations to support cell expansion, differentiation, and functionality.
- Ensuring GMP-compliance for media intended for preclinical and clinical-grade research.
- Cell Isolation Kits
- Development and supply of high-efficiency isolation kits for NK cells.
- Tailored solutions for isolating rare or challenging cell populations for research and therapeutic purposes.
- Streamlining isolation workflows to enhance reproducibility and scalability in clinical applications.
- Quality Assurance and Supply Chain Optimization
- Ensuring consistent quality and regulatory compliance of all culture media and kits supplied in Malaysia and the region.
- Establishing a robust supply chain to support Inno Therapeutics’ research and production needs.
- Co-developing solutions for cost-effective production to enhance accessibility for researchers and clinicians.
Strengths of BioMab Inc.
- Renowned expertise in the design and manufacture of culture media and biomedical kits.
- Advanced R&D facilities and a strong commitment to quality and innovation.
- Global presence with a track record of supporting leading biomedical research institutions.
Strengths of Inno Therapeutics
- Strong focus on developing and delivering advanced cellular and molecular therapeutics.
- Expertise in bridging research innovations to clinical applications.
- Strategic vision for fostering biomedical innovation in Malaysia and the ASEAN region.
Anticipated Outcomes
- Availability of high-quality, tailored culture media and isolation kits for diverse biomedical applications.
- Enhanced capacity for research and clinical development in regenerative medicine, cellular therapy, and immunotherapy.
- Accelerated translation of research into impactful therapeutic solutions, contributing to better healthcare outcomes in Malaysia and beyond.
